Ben, Besides costs there is ease of manufacture and long stable shelf life. Whilst we hear more amazing stories of success with cellular therapies, the costs and timelines involved make them a poor competitor to IMUs products. There is so much demand for cellular therapies, delays in manufacturing are long.
CF33 is incredibly cheap to manufacture in bulk. Since JPM and our Vaxinia updates, everyone knows about IMU. It doesn’t matter which aspect of the drug we look at CF33 is far superior to anything else being developed.
It won’t stay own with a MC of US$600M for ever. It will rerate to a price that reflects the value of its assets. Let’s hope 2024 is the year of the re-rate.
Why IMU is a multi multi bagger, page-21345
-
- There are more pages in this discussion • 5,440 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.8¢ |
Change
-0.002(4.00%) |
Mkt cap ! $356.9M | |||
| Open | High | Low | Value | Volume |
| 5.0¢ | 5.0¢ | 4.7¢ | $2.298M | 47.86M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 1925982 | 4.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.9¢ | 3452098 | 12 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| IMU (ASX) Chart |